Apr 24, 2017 by Brian FeroldiIs This Why Akari Therapetuics PLC Is Falling Today?After several positive clinical updates, shares of the rare-disease-focused biotech fell. Is this simply a matter of traders looking to book a profit from this red hot stock?
Apr 22, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhDWhy Now Is Not the Time to Buy Valeant PharmaceuticalsAre you thinking about buying into this former Wall Street darling? Here are three reasons why you might want to reconsider.
Apr 20, 2017 by Brian FeroldiI Can't Believe Intuitive Surgical, Inc. Just Spent $2 Billion on Stock BuybacksI'm a huge Intuitive Surgical bull, but with shares trading at a premium valuation, I question if this was really the best use of the company's capital.
Apr 20, 2017 by Brian Feroldi3 Top High-Yield Dividend Stocks to Buy NowPfizer, National Grid, and Retail Opportunity Investments all look like timely buys for income-focused investors.
Apr 19, 2017 by Brian Feroldi3 Beaten-Up Healthcare Stocks: Are They Bargains?The past year hasn't been kind to shareholders of Alexion Pharmaceuticals, Opko Health, and Novo Nordisk. Do their stocks hold value today, or should they be avoided?
Apr 19, 2017 by Brian Feroldi, Anders Bylund, and Matt DiLallo3 Mid-Cap Stocks to Buy in AprilOn the hunt for a few top-notch mid-cap stocks to add to your portfolio? Our team of Fools thinks Finisar, RSP Permian, and Veeva Systems are worthy of your attention.
Apr 16, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhD3 Big Reasons to Be Bullish on Biotech StocksHave you shied away from investing in the biotech sector? Here are three key reasons why you may want to reconsider that decision.
Apr 14, 2017 by Brian Feroldi, Anders Bylund, and Matt DiLallo3 Stocks That Could Double Your MoneyHere's why our team of Fools thinks that Emerge Energy Services, Finisar, and ViewRay all hold explosive upside potential.
Apr 14, 2017 by Brian Feroldi2 Incredibly Cheap High-Yield Dividend StocksTailored Brands and DineEquity both offer investors a huge yield and a dirt-cheap valuation, but is either company worthy of your capital today?
Apr 13, 2017 by Brian FeroldiWow! Americans Pay More for Healthcare per Person Than the 85 Cheapest Countries CombinedAmericans pay more for healthcare than nearly every other country in the world, yet we still don't crack the top 10 list of healthiest countries.
Apr 11, 2017 by Brian FeroldiThe 1 Stock You've Been Overlooking for Your Roth IRAThis high-flying stock offers double-digit growth prospects for the foreseeable future. That why I think it is an ideal candidate to add to your Roth IRA.
Apr 11, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhDThe 3 Top Dividend Stocks in the Healthcare SectorHere's why our team of contributors thinks Pfizer, Welltower, and Amgen are all terrific healthcare dividend stocks to buy right now.
Apr 10, 2017 by Brian Feroldi, Anders Bylund, and Matt DiLallo3 Stocks We're Never SellingWe Fools can't imagine ourselves ever hitting the sell button on these three businesses.
Apr 10, 2017 by Brian Feroldi3 Best Performing Stocks in MarchFind out why Micron Technology, FMC Corporation, and Vertex Pharmaceuticals were the best-performing stocks from the S&P 500 last month.
Apr 10, 2017 by Brian FeroldiWhy TherapeuticsMD Inc. Is Falling TodayShares tanked after the company announced that it received some bad news from the FDA related to TX-004HR.
Apr 8, 2017 by Brian Feroldi, Anders Bylund, and Matt DiLallo3 Stocks You Can Safely Own Until 2027Looking for a few stocks that can held for 10 years or more? Our team of contributors thinks that you should consider Red Hat, Enbridge, and Bladex.
Apr 8, 2017 by Brian Feroldi3 Bargain Stocks You Can Buy TodayHere's why Visa, EPAM Systems, and CVS Health could all be bargains hiding in plain sight.
Apr 7, 2017 by Brian FeroldiHere's Why Keryx Biopharmaceuticals Jumped 27.3% in MarchA series of positive announcements led to big gains in March.
Apr 7, 2017 by Brian FeroldiWhy PTC Therapeutics Dropped 25.3% in MarchA handful of negative developments overwhelmed the positive news items released during the month, causing the biotech's stock to crater.
Apr 6, 2017 by Brian Feroldi, Sean Williams, and George Budwell, PhDGilead Sciences: The Bull, the Bear and the Fence-SitterAre you considering buying or selling Gilead's stock today? Here's a range of viewpoints that can help you make a more informed decision.
